Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.提供用於藉由除化療及曲妥珠單抗之外亦投與培妥珠單抗來輔助治療人類患者之可手術HER2陽性原發性乳癌之方法。相較於在沒有培妥珠單抗之情況下投與曲妥珠單抗及化療，該等方法降低經診斷患有HER2陽性早期乳癌(eBC)之患者的侵襲性乳癌復發或死亡之風險。
